Table 1. Baseline characteristics.
| Baseline characteristics | Group S (N=15) | Group NS (N=29) | P value |
|---|---|---|---|
| Sex | 0.348 | ||
| Female | 10 (67%) | 15 (52%) | |
| Male | 5 (33%) | 14 (48%) | |
| Median of age (years) | 63 | 54 | |
| Primary tumor site | |||
| Stomach | 7 (47%) | 13 (45%) | 0.337 |
| Small bowel | 8 (53%) | 12 (41%) | |
| Colon | – | 2 (7%) | |
| Other | – | 2 (7%) | |
| Disease status | |||
| Metastatic de novo | 8 (53%) | 17 (59%) | 0.740 |
| Recurrent | 7 (47%) | 12 (41%) | |
| Metastatic organ | |||
| Liver | 9 (60%) | 16 (55%) | 0.246 |
| Peritoneum | 4 (27%) | 13 (45%) | 0.759 |
| Liver and peritoneum | 2 (13%) | – | – |
| Genotype of the primary tumor | |||
| KIT exon 11 mutation | 13 (86%) | 9 (31%) | |
| KIT exon 9 mutation | 1 (7%) | 2 (7%) | |
| Wild type | 1 (7%) | 5 (17%) | |
| Unknown | – | 13 (45%) | |
| Best response to IM | |||
| Complete response | – | 1 (3%) | |
| Partial response | 13 (87%) | 16 (55%) | 0.165 |
| Stable disease | 2 (13%) | 11 (38%) | |
| Not evaluated | – | 1 (3%) | |
Group S, treated with surgery group; Group NS, not treated with surgery group; IM, imatinib.